https://stockhub.co/index.php?action=history&feed=atom&title=Seelos_Therapeutics%2C_Inc.Seelos Therapeutics, Inc. - Revision history2026-07-31T01:16:12ZRevision history for this page on the wikiMediaWiki 1.43.5https://stockhub.co/index.php?title=Seelos_Therapeutics,_Inc.&diff=54353&oldid=prev>Paris: Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the..."2022-08-18T12:28:56Z<p>Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the..."</p>
<p><b>New page</b></p><div>== Summary<ref>Source: Yahoo Finance.</ref> ==<br />
<br />
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.<br />
<br />
== References and notes == <br />
[[Category:Thesis]]<br />
__INDEX__</div>>Paris